uniQure (NASDAQ: QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

Qure advances its pathology-shifting AMT-130 therapy for Huntington's disease; pivotal data and commercial launch prep target 2025 milestones.

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $37.7 million in its second quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 69 cents.

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 top ...

Qure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 ...

Qure (NASDAQ:QURE) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. The consensus EPS ...

Investing.com - uniQure N.V. (NASDAQ: QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s ...

uniQure N.V. (QURE) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

AudioCodes AUDC is estimated to report quarterly earnings at $0.14 per share on revenue of $60.05 million. • AstraZeneca AZN is expected to report quarterly earnings at $1.1 ...

uniQure N.V. Quarterly stock financials by MarketWatch. View the latest QURE financial statements, income statements and financial ratios.